Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin dose-escalation with paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer
ChiCTR1800015752Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Apr 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lobaplatin and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Chongqing University Cancer Hospital. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Apr 2018; status: recruiting.
02
Drugs
lobaplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR1800015752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015752.